MapLight Therapeutics (MPLT) Liabilities and Shareholders Equity (2024 - 2025)

MapLight Therapeutics (MPLT) reported Liabilities and Shareholders Equity of $479.5 million for Q4 2025, up 250.22% on a YoY basis from $136.9 million in Q4 2024, and up 86.42% sequentially from $257.2 million in Q3 2025.

MapLight Therapeutics (MPLT) Liabilities and Shareholders Equity (2024 - 2025) Analysis & Trends

MapLight Therapeutics (MPLT) has 2 years of Liabilities and Shareholders Equity data on file, last reported at $479.5 million in Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 250.22% year-over-year to $479.5 million; the trailing twelve-month figure through Dec 2025 stood at $873.6 million (changed N/A YoY), and the FY2025 full-year result was $479.5 million, up 250.22% from the prior year.
  • Liabilities and Shareholders Equity rose to $479.5 million in Q4 2025, from $257.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $479.5 million in Q4 2025 to a low of $136.9 million in Q4 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 MapLight Therapeutics 305.82 Mn 305.82 Mn - 479.51 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 479.51 Mn
Sep 30, 2025 257.22 Mn
Dec 31, 2024 136.92 Mn